Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Dr. Yasir Elamin at TexasLung25 brings us up to speed on ROS1 NSCLC – highlighting resistance and safety.
Emerging agents like taletrectinib and zidesamtinib promise to move the field even further!”
More posts featuring TexasLung25.
